One patient-evidence method.Calibrated to your asset stage.
The patient voice needed in clinical development is different from the voice needed at launch, HTA review, payer engagement, or post-launch growth.
Voice2Evidence scopes each engagement to your asset, indication, geography, and lifecycle stage — then translates patient voice into evidence-ready strategy for the teams that need to act.
Three inputs from you. Patient-voice evidence back.
You share the asset, indication, and lifecycle stage. We return patient-voice insights and strategic recommendations mapped to the functions that matter most.
Asset
Drug, molecule, brand, mechanism, or asset class.
Indication
Therapeutic area, patient segment, geography, and treatment context.
Lifecycle Stage
From clinical development to launch, access, and post-launch growth.
Patient voice translated into strategy for Medical Affairs, HEOR, Market Access, Regulatory Affairs, Commercial, Patient Engagement, and Leadership.
Five stages. One patient-evidence method.
Clinical Development
Patient burden, unmet need, quality-of-life priorities, and PRO / endpoint relevance.
Launch Readiness
Patient-centered evidence for medical strategy, education, positioning, and launch planning.
Regulatory & Evidence Planning
Patient experience insights that support evidence planning and patient-focused strategy discussions.
HTA & Market Access
Patient-relevant burden, quality-of-life, caregiver, access, and value narrative inputs.
Post-Launch Growth
Treatment experience, sentiment evolution, adherence, switching, education gaps, and lifecycle opportunities.
Voice2Evidence works across all five stages.
Impact is strongest at late-stage, launch, and post-launch, where patient voice directly shapes evidence, access, medical, and engagement decisions in a defined commercial window.
Tell us where you are in the lifecycle. We’ll show you what voice can become.
45-min strategic walkthrough · Confidential